Search Results

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

Entourage Health Corp. today announced its financial results for the three months ended March 31, 2024.

Royal Philips announced that it has completed the cancellation of 4,437,164 of its shares.

Syndax Pharmaceuticals announced that on April 1, 2024 the Company granted inducement awards to purchase up to 164,200 shares of common stock to ten new employees under the Company’s 2023 Inducement Plan.

Kezar Life Sciences, Inc. announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 164,000 shares of its common stock with an exercise price of $0.84 per share, which is equal to the closing price of Kezar’s common stock on May 1, 2024, the grant date of the awards.

According to Emergen Research, the global personalized therapy biosimulation market size was USD 1,061.7 million in 2020 and is expected to reach USD 3,164.1 million in 2028 and register a revenue CAGR of 14.6% during the forecast period, 2021-2028.

GI Windows Medical Corp, a clinical-stage, privately-held medical device company, announced a $16.4 million Series A-1 financing.

The global personalized therapy biosimulation market size reached USD 1,061.7 Million in 2020 and is expected to register a revenue CAGR of 14.6%, during the forecast period, according to latest analysis by Emergen Research.